Amarin Corp Plc (AMRN)

[biowreck]

Protecting the statin boys? Page 10 describes the FDA worry that a physician may misapprehend the health claim amarin seeks and thus prescribe vascepa instead of a dietary change or prescribed statin therapy! Seems lame to me. And page 7 what does FDA mean by "recommendation"...when it comes to dissemination of anchor trial data...as to educational or scientific settings, and what constitutes "appropriate background or training to distribute such materials"? Is Amarin allowed not to follow FDA recommendations should they choose so? And can a sales rep have the appropriate background or training?